



Receipt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

McKeon, et al

Application No: 09/575,580

Filed: May 20, 2000

For: CALCIPRESSINS: ENDOGENOUS
INHIBITORS OF CALCINEURIN,
USES AND REAGENTS RELATED
THERETO

RECEIVED

SEP 20 2001

TECH CENTER 1600/2900

Examiner: C. Kam

Art Unit: 1653

Attorney Document No. HMSU-P01-048

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

on June 18, 2001
Date


Karen DiRocco

REQUEST FOR CORRECTION OF FILING RECEIPT

Office of Initial Patent Examination
Customer Service Center
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Please make the following corrections in the formal Filing Receipt, a copy of which is enclosed and highlighted for your convenience, for the above-identified patent application:

Under the heading of Applicant(s), please correct the spelling from "Brooklina" to read "Brookline".

Should there be any questions concerning this request, the Examiner is invited to contact the undersigned at (617) 951-7000.


Respectfully Submitted,



Date: June 18, 2001

Customer No: 28120
Patent Group
Ropes & Gray
One International Place
Boston, MA 02110

David P. Halstead
Reg. No. 44,735
Tel. (617) 951-7000
Fax. (617) 951-7050



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 20 2001

Page 1 of 3

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/575,580	05/22/2000	1646	130	HMV-048.01	31	25	3

25181
FOLEY, HOAG & ELIOT, LLP
PATENT GROUP
ONE POST OFFICE SQUARE
BOSTON, MA 02109

FILING RECEIPT



OC000000005890470

Date Mailed: 03/22/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Frank McKeon, Boston, MA ;
Kimbara Kayako, ~~Brookline~~ **BROOKLINE**, MA ;
Sandy Ryeom, Brookline, MA ;R&D # HNSU-701-048
Action Corrected Filing Receipt
Due/Bar _____
By BR On 4-6-01

Continuing Data as Claimed by Applicant

Foreign Applications

If Required, Foreign Filing License Granted 08/02/2000

** SMALL ENTITY **

Title

Calcipressins: Endogenous inhibitors of calcineurin uses and reagents related thereto

Ropes & Gray
Intellectual Property Dept.

MAR 30 2001

Preliminary Class

514

RECEIVED

Data entry by : HALLMAN, LINDA

Team : 2800

Date: 03/22/2001

MAR 27 2001

PATENT DEPT.
DOCKETING

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

FILE COPY

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 1156

SERIAL NUMBER 09/575,580	FILING DATE 05/22/2000 RULE	CLASS 514	GROUP ART UNIT 1653	ATTORNEY DOCKET NO. HMSU-P01-048
------------------------------------	---	---------------------	-------------------------------	--

APPLICANTS

Frank McKeon, Boston, MA;
Kimbara Kayako, Brookline, MA;
Sandy Ryeom, Brookline, MA;

RECEIVED

SEP 20 2001

TECH CENTER 1600/2900

** CONTINUING DATA *****

** FOREIGN APPLICATIONS *****

IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** SMALL ENTITY **
** 08/02/2000

Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY MA	SHEETS DRAWING 31	TOTAL CLAIMS 7	INDEPENDENT CLAIMS 7
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged	Examiner's Signature	Initials		

ADDRESS

28120

TITLE

Calcipressins: Endogenous inhibitors of calcineurin uses and reagents related thereto

FILING FEE RECEIVED 580	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit